Skip to main content
. 2020 Nov 24;11(47):4457–4462. doi: 10.18632/oncotarget.27807

Figure 4.

Figure 4

(A) baseline CT scan and (B) response obtained after three months of neoadjuvant cabozantinib, with a reduction of the left kidney mass from 66.8 to 55.5 mm and of the SRL nodule from 12.1 to 10.8 mm. (C) Last reassessment CT scan, after CN, showing only stability of the remaining solitary lung metastases which is pending surgery.

HHS Vulnerability Disclosure